Cigna Updates Medical Policy to Cover Hologic’s Acessa® Procedure, Expanding Access to Millions of Women Across the Country
June 03 2021 - 4:27PM
Business Wire
New Coverage Further Validates
Laparoscopic Radiofrequency Ablation (Lap-RFA) as a Standard of
Care for Uterine Fibroids
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health,
announced today that Cigna, one of the largest global health
insurance service companies, has updated its medical policy to
cover the Acessa® Laparoscopic Radiofrequency Ablation (Lap-RFA)
procedure (CPT code 58674) as medically necessary.
In less than eight months, the number of people covered for the
Acessa procedure has grown by 18 million, resulting in more than 75
million commercially insured people covered to-date with
significantly expanded coverage in almost every state.
“For too long, limited insurance coverage of less invasive
fibroid treatment options has caused women to settle for
interventions that may not align with their treatment goals,” said
Essex Mitchell, division president, GYN Surgical Solutions,
Hologic. “Cigna’s decision to cover the Acessa procedure grants
providers the opportunity to offer more women a treatment option
that can best support their desired health outcomes.”
For the estimated three in four women in the U.S. who are
affected by fibroids, access to the full spectrum of treatment
options has been limited in large part due to a lack of insurance
coverage for procedures beyond hysterectomy.1 Cigna’s coverage
decision will go a long way toward removing barriers to
evidence-based, minimally invasive treatment options for uterine
fibroids.
“Cigna’s new policy to reimburse Acessa Lap-RFA as a medically
necessary procedure will enable millions of women suffering from
fibroids to get the care they deserve,” says Dr. Jay Berman,
professor and vice chair OBGYN Dept. Wayne State University Medical
School, DMC Harper/Hutzel Chief of Gynecology Services. “Coming on
the heels of the updated ACOG PB228 guidance, this policy is yet
another step in the right direction to ensuring women have a choice
in their fibroid treatment that is not limited by what their
insurance will or will not cover.”
The Acessa procedure can provide significant improvements to the
symptoms caused by fibroids while preserving the uterus and is
therefore an important treatment option for women who would
otherwise require more invasive interventions.2 This outpatient
procedure results in less recovery time than more invasive
interventions and allows patients to return to work within four to
five days.2 For more information about the benefits and risks of
the Acessa procedure, visit www.AcessaProcedure.com.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company
primarily focused on improving women's health and well-being
through early detection and treatment. For more information on
Hologic, visit www.hologic.com.
Forward-Looking
Statements
This press release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic’s Acessa product. There can be no assurance this
product will achieve the benefits described herein or that such
benefits will be replicated in any particular manner with respect
to an individual patient. The actual effect of the use of the
product can only be determined on a case-by-case basis depending on
the particular circumstances and patient in question. In addition,
there can be no assurance that this product will be commercially
successful or achieve any expected level of sales. Hologic
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements presented
herein to reflect any change in expectations or any change in
events, conditions, or circumstances on which any such statements
are based.
Hologic, Acessa, and The Science of Sure are trademarks and/or
registered trademarks of Hologic, Inc. and/or its subsidiaries in
the United States and/or other countries.
References
1 Al-Hendy A, Myers ER, Stewart E. Uterine Fibroids: Burden and
Unmet Medical Need. Semin Reprod Med. 2017;35(6):473-480.
doi:10.1055/s-0037-1607264 2 SG Chudnoff, et al. Outpatient
Procedure for the Treatment and Relief of Symptomatic Uterine
Myomas. Obstetrics and Gynecology, 2013;121(5):1075-82.
SOURCE: Hologic, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210603006035/en/
Jane Mazur (508) 263-8764 (direct) (585) 355-5978 (mobile)
Jane.Mazur@hologic.com
Michael Watts (858) 410-8588 Michael.Watts@hologic.com
Hologic (NASDAQ:HOLX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Hologic (NASDAQ:HOLX)
Historical Stock Chart
From Sep 2023 to Sep 2024